PURR
NASDAQ · Biotechnology
Hyperliquid Strategies
$4.93
+0.26 (+5.57%)
Open$5.01
Previous Close$4.67
Day High$5.05
Day Low$4.65
52W High$5.78
52W Low$3.01
Volume—
Avg Volume5.58M
Market Cap626.24M
P/E Ratio—
EPS—
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+243.8% upside
Current
$4.93
$4.93
Target
$16.95
$16.95
$12.34
$16.95 avg
$26.10
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 243.91M | 233.99M | 197.33M |
| Net Income | 21.63M | 22.04M | 17.71M |
| Profit Margin | 8.9% | 9.4% | 9.0% |
| EBITDA | 48.94M | 46.22M | 40.39M |
| Free Cash Flow | 24.46M | 20.15M | 20.27M |
| Rev Growth | -3.3% | +11.1% | +4.4% |
| Debt/Equity | 0.58 | 0.61 | 0.58 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |